Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNAMIC trial in oncogene-addicted metastatic non-small cell lung cancer
2026-525268-16-00Phase 3Authorised
- Sponsor
- University of Turin
- Start
- Oct 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of osimertinib, lazertinib, amivantamab, alectinib, brigatinib and 22 more in non-small cell lung cancer (NSCLC), sponsored by University of Turin. Primary endpoint: PFS2 at two years. Planned start Oct 2026; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2026-525268-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525268-16-00.